Jonathan Barkman | Founder
Heme Solutions

Jonathan Barkman is a visionary leader and the Founder of Heme Solutions, a pioneering biotech company dedicated to advancing treatments for rare diseases. Mr. Barkman has over 30 years of experience in the finance industry and has spent the last 5 years evaluating advanced complex heme-carbohydrate and polysaccharide polymer-based science. Working with innovators around the world he has assisted in the launch of Bioxitran (BIXT) and created the HEME Foundation and HEME Solutions. Mr. Barkman is dedicated to the pursuit of bringing a Universal Oxygen Carrier (UOC), a potential Blood Substitute and other new therapeutics to market. Mr. Barkman is a passionate advocate for orphan drug development and improving the lives of patients with rare diseases. Mr. Barkman started his highly successful career initial as a registered Wealth Advisor and eventually moved to serve as First Vice President of investments at a top Wall Street firm. After his time on Wall Street, he founded Riverview Capital Enterprises LLC and still serves as its CEO today. Mr. Barkman's expertise lies in identifying unmet medical needs and developing innovative solutions to address them. Under his leadership, Heme Solutions is evaluating a number of opportunities by which it’s UOC technology can impact the orphan drugs to market, transforming the treatment landscape for rare diseases and providing hope to patients and their families. Mr. Barkman is a graduate of Churchman School of Business, has been a trusted board member and advisor to many private and public companies. Capitalizing on his relationship building and business development experience he has established himself as a needed asset in the successful launch and growth with multiple companies over the years.
As a speaker at World Orphan Drug Congress USA 2026, Mr. Barkman will share his insights on the latest trends and advancements in orphan drug development. His thought-provoking presentations are not to be missed, offering valuable perspectives on the future of rare disease treatment and the critical role of innovation in improving patient outcomes.